Login
Login

APHRC Online Microdata Library
  • Home
  • About APHRC
  • Datasets
  • Collections
  • Citations
  • Resources
  • How to use it?
  • Why sharing data?
  • Contact us
    Home / Central Data Catalog / HEALTH_AND_WELL-BEING / DDI-KEN-APHRC-GEGO-2021-V1.0 / variable [V121]
Health_and_Well-Being

Healthcare and Socio-economic Impacts of COVID-19 on Patients with Diabetes in Selected Counties in Kenya, GECO-Kenya

Kenya, , 2021 - 2023
Health and Well-Being (HaW)
Gershim Asiki,MD,Phd
Last modified November 26, 2024 Page views 38621 Documentation in PDF Metadata DDI/XML JSON
  • Study description
  • Documentation
  • Data Description
  • Get Microdata
  • Data files
  • GECO_FinalData1
CSV JSON

(ii) (a) Mls of insulin (q3p8c2a)

Data file: GECO_FinalData1

Overview

vald 485
invd 0
Interval discrete

Questions and instructions

Literal question
Think about the 3 months after [COVID]. Please indicate:
Fikiria kuhusu miezi 3 baada ya [COVID], kisha ueleze;
(a)Frequency (e.g. once/day; twice/month)
Ni mara ngapi (k.m. mara moja kwa siku; mara mbili kwa mwezi)
Categories
Value Category Cases
0 372
91%
00 9
2.2%
10 3
0.7%
10 and 12 1
10 morning 12 evening 1
10 morning 5 evening 1
10 morning 6evening 1
10mls evening, 22mls morning 1
10mls twice 1
11mls morning and 13 mls evening 1
12 1
0.2%
12 morning 6 evening 1
12mls morning,6mls evening 1
14mls morning,10mls evening 1
14ms 1
16 evening 24 morning 1
16 mls morning and 8 mls evening 1
16mls morning 8mls evening 1
18 ml in the morning 9 in the evening 1
19ml 1
2 1
0.2%
20 2
0.5%
20 iu 1
20 mls morning 10mls evening 1
20 mls morning and 40 mls evening 1
20 mls morning, 10 mls evening 1
20 mls morning; 10 mls evening 2
20 mls morning;10mls evening 1
20 morning 10 evening 1
20 morning 12 evening 1
20 morning, 10 evening 1
20 units 1
20mls morning and 10mls evening 1
20mls morning,10mls evening 1
20mls morning,15mls evening 1
20mls/morning,10mls evening 1
20morning, 10 evening 1
22 MIs and 10 MIs 1
22 morning, 12 evening 1
22mls morning,11mls evening 1
24 mls morning and 12 mls evening 1
24 morning 12 evening 1
24 morning 12 evening 1
24ml 1
24mls 1
24mls morning and 14 mls evening 1
24mls morning,12mls evening 1
25 morning 12evening 1
26 2
0.5%
26 , morning 12 afternoon 1
26 morning 10 evening 1
26 morning, 15 evening 1
26morning, 14 evening 1
28 1
0.2%
28 morning 18 evening 1
28MIs and 14MIs 1
30 4
1%
30 mls morning: 18mls evening 1
30mls morning 10mls evening 1
30mls morning, 10mls evening 1
33 1
0.2%
34 Mls Morning:17 Mls Evening 1
34 mls morning and 18mls evening 1
34ml 1
35 1
0.2%
35 morning, 15 evening 1
36 2
0.5%
36 Mls morning; 24 Mls Evening 1
36mls 2
36mls/20mls 1
38 1
0.2%
39 1
0.2%
40 mls morning and 20 mls evening 1
40 morning 20 evening 1
40mls morning,22 mls evening 1
42/20 1
45 1
0.2%
46 1
0.2%
48 morning, 23evening 1
48ml 2
50ml 2
58 1
0.2%
6 1
0.2%
6 morning 4 morning 1
60 1
0.2%
68 1
0.2%
7 morning 7 evening 1
70ml 1
8ml 1
9 2
0.5%
9ml 1
Glocoment,nifiat no glotoment 1
O 1
Warning: these figures indicate the number of cases found in the data file. They cannot be interpreted as summary statistics of the population of interest.
Question pretext
Medications
Has this changed in [COVID] period = the time you were most affected [if applicable]
Question post text
N/A
Interviewer instructions
N/A

Description

Text
The question was asked to patients with type 2 diabetes to indicate the dose of insulin they used during the three months of COVID-19 pandemic, specifically between March and June 2020.
Universe
Patients with type 2 diabetes

others

Notes
"(ii) (a) Mls of insulin"
APHRC Microdata Portal

© APHRC Microdata Portal, All Rights Reserved. Slot Online